PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples